IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 5.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,696 shares of the medical research company's stock after selling 1,592 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in IQVIA were worth $4,554,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in IQV. Continuum Advisory LLC boosted its holdings in IQVIA by 3.7% during the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock valued at $354,000 after acquiring an additional 64 shares during the period. ST Germain D J Co. Inc. increased its stake in IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after purchasing an additional 76 shares during the period. Zions Bancorporation N.A. lifted its position in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after purchasing an additional 85 shares in the last quarter. Quadrant Capital Group LLC boosted its stake in shares of IQVIA by 10.7% in the fourth quarter. Quadrant Capital Group LLC now owns 928 shares of the medical research company's stock valued at $182,000 after purchasing an additional 90 shares during the period. Finally, Utah Retirement Systems grew its holdings in shares of IQVIA by 0.3% in the fourth quarter. Utah Retirement Systems now owns 29,959 shares of the medical research company's stock valued at $5,887,000 after purchasing an additional 100 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of NYSE:IQV traded down $0.41 on Thursday, reaching $164.24. The company's stock had a trading volume of 674,106 shares, compared to its average volume of 1,651,146. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $252.88. The stock has a market capitalization of $28.41 billion, a P/E ratio of 22.38, a PEG ratio of 1.83 and a beta of 1.30. The stock's 50-day moving average is $150.32 and its two-hundred day moving average is $173.74. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The company had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The firm's revenue for the quarter was up 2.5% on a year-over-year basis. During the same period last year, the firm earned $2.54 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of recent research reports. Redburn Partners set a $188.00 target price on IQVIA in a report on Friday, May 23rd. HSBC lowered IQVIA from a "buy" rating to a "hold" rating and reduced their price target for the company from $260.00 to $160.00 in a research report on Friday, April 25th. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research note on Monday, May 19th. Citigroup reiterated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Finally, Wall Street Zen downgraded shares of IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and a consensus target price of $226.32.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.